rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + Meningococcal C oligosaccharide conjugated vaccine + Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine
Phase 3Completed 0 watching 0 views this week📈 Rising Meningococcal Disease, Meningococcal Meningitis
Apr 1, 2011 → Dec 1, 2014
About rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + Meningococcal C oligosaccharide conjugated vaccine + Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine
rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + Meningococcal C oligosaccharide conjugated vaccine + Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine is a phase 3 stage product being developed by Novartis for Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01339923. Target conditions include Meningococcal Disease, Meningococcal Meningitis.
Clinical Trials (1)
| NCT ID | Phase | Status | Start | Completion | Indication |
|---|
| NCT01339923 | Phase 3 | Completed | Apr 1, 2011 | Dec 1, 2014 | Meningococcal Disease |
| Product | Company | Stage | Hype Score |
|---|
| RotaTeq® + NeisVac-C® | Merck | Phase 3 | |
| Meningococcal C conjugate vaccine | Novartis | Approved | |
| Meningococcal (group B) multicomponent recombinant adsorbed vaccine. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV) | Novartis | Phase 2 | |
| Meningococcal ACWY-CRM conjugate vaccine + Meningococcal ACWY-PS polysaccharide vaccine | Novartis | Phase 3 | |
| 1a - rMenB+OMV NZ and routine vaccines + 1b - rMenB+OMV NZ and routine vaccines + 2a - Routine and rMenB+OMV NZ vaccines + 2b - rMenB+OMV NZ and routine vaccines + 3a - rMenB+OMV NZ and routine vaccines + 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations + 4a- rMenB+OMV NZ and routine vaccines + 4b - rMenB+OMV NZ and routine vaccines | Novartis | Phase 3 | |
| MenACWY-CRM | Novartis | Pre-clinical | |
| Meningococcal C conjugate vaccine | Novartis | Approved | |
| Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine | Novartis | Approved | |
| rMenB + rMenB+OMV NZ | Novartis | Phase 2 | |
| Typhoid Vi Polysaccharide Vaccine + Yellow Fever Vaccine + Japanese Encephalitis Vaccine + Rabies Vaccine + MenACWY-CRM Vaccine | Novartis | Phase 3 | |
| rMenB+OMV NZ | Novartis | Phase 3 | |
| Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP | Novartis | Phase 3 | |
| Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + Tdap | Novartis | Phase 2 | |
| MenACWY-CRM | Novartis | Phase 3 | |
| rMenB + rMenB+OMV | Novartis | Phase 2 | |
| MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV | Novartis | Phase 2 | |
| Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV. | Novartis | Phase 2 | |
| MenABCWY+OMV + MenABCWY+¼OMV + Placebo | Novartis | Phase 2 | |
| Novartis MenACWY-CRM + Saline Placebo | Novartis | Phase 3 | |
| rMenB+OMV NZ + Placebo | Novartis | Phase 2/3 | |
Other Products from Novartis